Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis

NCT03828123 is registered in ClinicalTrials.gov with Bioinova, s.r.o. as lead sponsor.

NCT NCT03828123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03828123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis
Lead sponsor
Bioinova, s.r.o.
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2012
Completion date
August 18, 2017
Enrollment
26 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

motor neuron disease, amyotrophic lateral sclerosis